Abstract
Cyclooxygenase and lipoxygenase metabolism of arachidonic acid produces compounds important in cardiovascular diovascular control. Further, arachidonic acid can be metabolised by cytochrome p450 to produce epoxyeicosatrienoic acids (EETs). These derivatives are inactivated by soluble epoxide hydrolase (sEH). The potential role of these EETs in hypertension and cardiac remodelling has been determined using the selective sEH inhibitor, N-adamantyl-N′-dodecylurea (ADU), in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Experiments were performed on male Wistar rats following uninephrectomy alone (UNX rats) or uninephrectomy with administration of DOCA (25 mg every fourth day subcutaneously) and 1% NaCl in drinking water (DOCA-salt rats). ADU (10 mg/kg/d subcutaneously) was administered for 2wk starting 2wk after surgery. Cardiovascular structure and function were determined using organ wet weights, histological analysis of collagen and inflammation, isolated heart and thoracic aortic ring preparation, and electrophysiological measurements. DOCA-salt hypertensive rats developed hypertension, hypertrophy, perivascular and interstitial fibrosis, endothelial dysfunction, and prolongation of the cardiac action potential duration within 4 wk. Administration of ADU prevented the further increase in systolic blood pressure and left-ventricular wet weight and normalized endothelial function. ADU treatment did not change inflammatory cell infiltration, collagen deposition, or cardiac action potential duration. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities.
References
Fletcher, J. R. (1993) Eicosanoids. Critical agents in the physiological process and cellular injury. Arch Surg. 128, 1192–1196.
Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 82, 131–185.
Capdevila, J. H. and Falck, J. R. (2001) the CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun. 285, 571–576.
Wu, S., Chen, W., Murphy, E., et al. (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem. 272, 12,551–12,559.
Node, K., Ruan, X. L., Dai, J., et al. (2001) Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276, 15,983–15,989.
Sun, J., Sui, X., Bradbury, J. A., Zeldin, D. C., Conte, M. S., and Liao, J. K. (2002) Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90, 1020–1027.
Node, K., Huo, Y., Ruan, X., et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276–1279.
Muthalif, M. M., Karzoun, N. A., Gaber, L., et al. (2000) Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36, 604–609.
Messer-Letienne, I., Bernard, N., Roman, R. J., Sassard, J., and Benzoni, D. (1999) Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Am. J. Hypertens. 12, 398–404.
Sacerdoti, D., Escalante, B., Abraham, N. G., McGiff, J. C., Levere, R. D., and Schwartzman, M. L. (1989) Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243, 388–390.
Stec, D. E., Deng, A. Y., Rapp, J. P., and Roman, R. J. (1996) Cytochrome P450 4A genotype cosegregates with hypertension in Dahl S rats. Hypertension 27, 564–568.
Lapuerta, L., Chacos, N., Falck, J. R., Jacobson, H., and Capdevila, J. H. (1988) Renal microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Am. J. Med. Sci. 295, 275–279.
Capdevila, J. H., Wei, S., Yan, J., et al. (1992) Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem. 267, 21,720–21,726.
Makita, K., Takahashi, K., Karara, A., Jacobson, H. R., Falck, J. R., and Capdevila, J. H. (1994) Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest. 94, 2414–2420.
Holla, V. R., Makita, K., Zaphiropoulos, P. G., and Capdevila, J. H. (1999) The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest. 104, 751–760.
Takahashi, K., Harris, R. C., Capdevila, J. H., et al. (1993) Induction of renal arachidonate cytochrome P-450 epoxygenase after uninephrectomy: counterregulation of hyperfiltration. J. Am. Soc. Nephrol. 3, 1496–1500.
Morisseau, C., Goodrow, M. H., Dowdy, D., et al. (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. USA 96, 8849–8854.
Davis, B. B., Thompson, D. A., Howard, L. L., Morisseau, C., Hammock, B. D., and Weiss, R. H. (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 99, 2222–2227.
Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C., and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690–694.
Yu, Z., Davis, B. B., Morisseau, C., et al. (2004) Vascular localization of soluble epoxide hydrolase in the human kidney. Am. J. Physiol. Renal. Physiol. 286, F720-F726.
Yu, Z., Xu, F., Huse, L. M., et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992–998.
Zhao, X., Yamamoto, T., Newman, J. W., et al. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15, 1244–1253.
Brown, L., Duce, B., Miric, G., and Sernia, C. (1999) Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the reninangiotensin system. J. Am. Soc. Nephrol. 10(Suppl 11), S143-S148.
Miric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S. M., and Brown, L. (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133, 687–694.
Smith, K. R., Pinkerton, K. E., Watanabe, T., Pedersen, T. L., Ma, S. J., and Hammock, B. D. (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA 102, 2186–2191.
Sinal, C. J., Miyata, M., Tohkin, M., Nagata, K., Bend, J. R., and Gonzalez, F. J. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275, 40,504–40,510.
Hu, S., and Kim, H. S. (1993) Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur. J. Pharmacol. 230, 215–221.
Satoh, T., Cohen, H. T., and Katz, A. I. (1993) Intracellular signaling in the regulation of renal Na−K-ATPase. II. Role of eicosanoids. J. Clin. Invest. 91, 409–415.
He, H., Podymow, T., Zimpelmann, J., and Burns, K. D. (2003) NO inhibits Na+−K+-2Cl-contransport via a cytochrome P-450-dependent pathway in renal epithelial cells (MMDD1). Am. J. Physiol. Renal Physiol. 284, F1235-F1244.
Fornage, M., Hinojos, C. A., Nurowska, B. W., et al. (2002) Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40, 485–490.
Catella, F., Lawson, J. A., Fitzgerald, D. J., and FitzGerald, G. A. (1990) Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc. Natl. Acad. Sci. USA 87, 5893–5897.
Fornage, M., Boerwinkle, E., Doris, P. A., Jacobs, D., Liu, K., and Wong, N. D. (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335–339.
Sato, K., Emi, M., Ezura, Y., et al. (2004) Soluble epoxide hydrolase variant (Glu287 Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet. 49, 29–34.
Sheu, H. L., Omata, K., Utsumi, Y., et al. (1995) Epoxyeicosatrienoic acids stimulate the growth of vascular smooth muscle cells. Adv. Prostaglandin Thromboxane Leukot. Res. 23, 211–213.
Karam, H., Heudes, D., Gonzales, M. F., Loffler, B. M., Clozel, M., and Clozel, J. P. (1996) Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am. J. Hypertens. 9, 991–998.
Owens, G. K., Rabinovitch, P. S., and Schwartz, S. M. (1981) Smooth muscle cell hypertrophy versus hyperplasia in hypertension. Proc. Natl. Acad. Sci. USA 78, 7759–763.
Konishi, M., and Su, C. (1983) Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 5, 881–886.
Luscher, T. F., Raij, L., and Vanhoutte, P. M. (1987) Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 9, 157–163.
Van de Voorde, J., and Leusen, I. (1986) Endothelium-dependent and independent relaxation of aortic rings from hypertensive rats. Am J Physiol. 250, H711-H717.
Nunes, V. W., Fortes, Z. B., Nigro, D., Carvalho, M. H., Zorn, T. M., and Scivoletto, R. (2000) Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. Gen. Pharmacol. 34, 117–125.
Weintraub, N. L., Fang, X., Kaduce, T. L., VanRollins, M., Chatterjee, P., and Spector, A. A. (1999) Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am. J. Physiol. 277, H2098-H2108.
Coulombe, A., Momtaz, A., Richer, P., Swynghedauw, B., and Coraboeuf, E. (1994) Reduction of calcium-independent transient outward potassium current density in DOCA salt hypertrophied rat ventricular myocytes. Pflugers Arch. 427, 47–55.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loch, D., Hoey, A., Morisseau, C. et al. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble expoxide hydrolase. Cell Biochem Biophys 47, 87–97 (2007). https://doi.org/10.1385/CBB:47:1:87
Issue Date:
DOI: https://doi.org/10.1385/CBB:47:1:87